Fuller & Thaler Asset Management, Inc. filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing a 1.84% stake in Collegium Pharmaceutical Inc as of September 30, 2026.

Key Highlights

  • Reporting firm: Fuller & Thaler Asset Management, Inc., a California-based investment adviser, is the filing party.
  • Shares beneficially owned: 598,540.14 shares of Collegium Pharmaceutical Inc common stock (CUSIP 19459J104).
  • Percentage of class: The aggregate position represents 1.84% of the outstanding class of common stock.
  • Voting and dispositive power: Fuller & Thaler reported sole voting power and sole dispositive power over all 598,540.14 shares, with no shared voting or dispositive power.
  • Triggering date: The event requiring this filing occurred on September 30, 2026, and the statement is designated as Amendment No. 1.
  • Ordinary course certification: The filing certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Fuller & Thaler Discloses Amended Position in Collegium Pharmaceutical

Fuller & Thaler Asset Management, Inc., headquartered at 411 Borel Avenue, Suite 300, San Mateo, California, filed this amended statement to report its beneficial ownership in Collegium Pharmaceutical Inc (NASDAQ:COLL), a specialty pharmaceutical company whose principal executive offices are located at 100 Technology Center Drive, Suite 300, Stoughton, Massachusetts 02072. The amendment, designated Amendment No. 1, updates a prior filing and reflects ownership as of September 30, 2026.

According to the filing, Fuller & Thaler holds 598,540.14 shares of Collegium common stock, representing 1.84% of the class. The firm reported sole voting power and sole dispositive power over the full 598,540.14 shares, with zero shares subject to shared voting or shared dispositive arrangements. Fuller & Thaler is classified in the filing as an investment adviser (type "IA") organized under the laws of California.

The statement was signed by Hanna Zanoni, Chief Compliance Officer of Fuller & Thaler Asset Management, Inc., on November 16, 2026. Item 5 of the filing designates this as an ownership position of 5 percent or less of the class. Items 6 through 9 were each noted as "Not Applicable," indicating no ownership on behalf of another person, no subsidiary involvement, and no group membership or dissolution notice.

What Was Disclosed

Fuller & Thaler Asset Management, Inc. disclosed beneficial ownership of 598,540.14 shares of Collegium Pharmaceutical Inc common stock, equal to 1.84% of the class, with full sole voting and dispositive power, in an amended filing dated November 16, 2026 and reflecting a September 30, 2026 event date.